GPCR Therapies: 8 Promising Biotechs Bolstering RD
- In the next 6 months, we can expect to see the launch of phase 2 trials for several GPCR-targeted drugs, including Structure Therapeutics’ GSBR-1290 for obesity treatment and Tectonic Therapeutics’ TX45 for pulmonary hypertension.
- Within the next year, we anticipate the approval of at least one GPCR-targeted drug, potentially Confo Therapeutics’ CFTX-1554 for neuropathic pain, which is currently in phase 1 trials.
- In the next 5 years, the GPCR therapy market is expected to reach $10 billion, with several biotechs, including Domain Therapeutics and Teon Therapeutics, making significant progress in their pipelines.
- By 2033, GPCR-targeted therapies are likely to become a standard treatment option for various diseases, with the market size reaching $20 billion and several biotechs becoming household names in the industry.
Tags: billion, cancer, development, industry, pharmacy
